No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy

Scandinavian Cardiovascular Journal

Volumn 47, Issue 2, 2013, Pages 80-87

  Bogsrud, Martin Proven ^a,b   Langslet, Gisle ^b   Ose, Leiv ^b   Arnesen, Kjell Erik ^b   Sm Stuen, Milada Cvancarova ^b   Malt, Ulrik Fredrik ^b   Woldseth, Berit ^b   Retterstol, Kjetil ^b  

^a Møre and Romsdal Health Trust   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Q10; Selenium; Statin induced myopathy

Indexed keywords

ATORVASTATIN; MYOQUINON; PLACEBO; SELENIUM; SELENIUM PRECISE; UBIDECARENONE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MUSCLE FUNCTION; MYOPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATIN INDUCED MYOPATHY; SUPPLEMENTATION; TREATMENT DURATION;

ADULT; AGED; ANTIOXIDANTS; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MUSCULAR DISEASES; PROSPECTIVE STUDIES; PYRROLES; QUESTIONNAIRES; SELENIUM; TREATMENT OUTCOME; UBIQUINONE; VITAMINS;

EID: 84875464334     PISSN: 14017431     EISSN: 16512006     Source Type: Journal    
DOI: 10.3109/14017431.2012.756119     Document Type: Article

References (26)

1. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681-90.
2. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-14.
3. Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment . Drug Saf. 2010;33:171-87.
4. Laaksonen R. On the mechanisms of statin-induced myopathy. Clin Pharmacol Ther. 2006;79:529-31.
5. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858-68.
6. Quinzii CM, DiMauro S, Hirano M. Human coenzyme Q10 deficiency. Neurochem Res. 2007;32:723-7.
7. Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G. Coenzyme Q10 in neuromuscular and neurodegenerative disorders. Curr Drug Targets. 2010;11:111-21.
8. Kumar A, Kaur H, Devi P, Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther. 2009;124:259-68.
9. Mortensen SA, Leth A, Agner E, Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med. 1997;18:S137-44.
10. Bargossi AM, Grossi G, Fiorella PL, Gaddi A, Di GR, Battino M. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med. 1994;15:S187-93.
11. Mabuchi H, Nohara A, Kobayashi J, Kawashiri MA, Katsuda S, Inazu A, Koizumi J; Hokuriku Lipid Research Group. Effects of CoQ10 supplementation on plasma lipo-protein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. Atherosclerosis. 2007;195: 182-9.
12. Young JM, Florkowski CM, Molyneux SL, McEwan RG, Frampton CM, George PM, Scott RS. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. Am J Cardiol. 2007;100:1400-3.
13. Caso G, Kelly P, McNurlan MA, Lawson WE. Effect of coen-zyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol. 2007;99:1409-12.
14. Bookstaver DA, Burkhalter NA, Hatzigeorgiou C. Effect of Coenzyme Q10 Supplementation on Statin-Induced Myalgias. Am J Cardiol. 2012;110:526-9.
15. Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet. 2004;363:892-4.
16. Golomb BA, Kane T, Dimsdale JE. Severe irritability associated with statin cholesterol-lowering drugs . QJM. 2004;97: 229-35.
17. Brähler E, Scheer J. 1983. Der Giessener Beschwerdebogen (GBB). Bern: Huber.
18. Vassend O, Lian L, Andersen HT. [Norwegian version of NEOPersonality Inventory, Symptom Checklist 90 Revised, and Giessen Subjective Complaints List]. Tidsskr NorP-sykologforen. 1992;29:1150-60.
19. Malt UF, Nerdrum P, Oppedal B, Gundersen R, Holte M, Lone J . Physical and mental problems attributed to dental amalgam fillings: a descriptive study of 99 self-referred patients compared with 272 controls. Psychosom Med. 1997;59:32-41.
20. Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol. 1992;63:452-9.
21. Nashef L, Lane RJM. Screening for mitochondrial cytopa-thies: the sub-anaerobic threshold exercise test (SATET). J Neurol Neurosurg Psychiatry. 1989;52:1090-4.
22. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485-9.
23. Todd KH. Clinical versus statistical significance in the assessment of pain relief. Ann Emerg Med. 1996;27:439-41.
24. Laaksonen R, Riihimaki A, Laitila J, Martensson K, Tikkanen MJ, Himberg JJ. Serum and muscle tissue ubiquinone levels in healthy subjects. J Lab Clin Med. 1995;125:517-21.
25. Laaksonen R, Jokelainen K, Sahi T, Tikkanen MJ, Himberg JJ. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther. 1995;57:62-6.
26. Mohaupt MG, Karas RH, Babiychuk EB, Sanchez-Freire V, Monastyrskaya K, Iyer L, et al. Association between statin-associated myopathy and skeletal muscle damage. CMAJ. 2009;181:11-8.